E5103 Epirubicin Supplemental Form NCT00433511 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Source Form: NCI FormBuilder:

  1. 8/26/12 8/26/12 -
  2. 1/8/15 1/8/15 - Martin Dugas
  3. 6/8/15 6/8/15 -
Uploaded on:

June 8, 2015

To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

E5103 Epirubicin Supplemental Form NCT00433511

INSTRUCTIONS: Complete and submit this form at the end of each cycle of Step 1 during the Doxorubicin shortage IF Doxorubicin was not administered due to drug shortage. On the E5103 Treatment Form - Step 1, for Doxorubicin, be sure to record ¿0.0mg¿ for Agent Total Dose, "02=dose held" for Dose Modification and ¿06=alternative therapy for other reason" for Dose Modification Reason

Patient demographics
Data amendment
Treatment period
On Treatment Report Period (Choose one X)
Dose modification
Dose Modification Reason (If a dose modification reason was due to an Adverse Event, please record all AE grades both reportable and non-reportable in the appropriate section on E5103 Adverse Event form.)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial